telisotuzumab vedotin phase 1

CancerLinQ Second- and third-line Tx options are limited to chemotherapy-based regimens with limited efficacy and significant toxicities. The ORR was deemed modest in the squamous and EGFR-mutated cohorts.1, Grade 3 adverse events (AEs) occurred in 44% of patients receiving teliso-V. This phase 1 openlabel study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of telisotuzumab vedotin in Japanese patients with advanced solid. This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). Telisotuzumab vedotin. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. 2021 May;22(3):170-177. doi: 10.1016/j.cllc.2020.09.013. providing strong rationale for dual targeting. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Newest Articles The clinical development of telisotuzumab vedotin focusses on MET overexpressing tumors, especially NSCLC. In a phase 1/1b study (NCT02099058) in patients (pts) with c-Met OE NSCLC, Teliso-V alone or in combination with erlotinib demonstrated an acceptable safety profile and antitumor activity. Faiella A, Riccardi F, Carten G, Chiurazzi M, Onofrio L. J Oncol. FOIA This phase 1, openlabel, doseescalation clinical trial was conducted at two sites in Japan (NCT03311477). Careers. Contact Us Patients with adenosquamous histology or major surgery within 21 days prior to the first dose of teliso-v are not eligible to participate. Privacy Policy. TELISOTUZUMAB VEDOTIN [WHO-DD] Sources: Common Name English Classification Tree Code System Code; Source: NCI_THESAURUS C1512. JCO Oncology Practice Telisotuzumab vedotin - AbbVie Alternative Names: ABBV-399; ABT 399; Teliso-V; Telisotuzumab-vedotin Latest Information Update: 01 Jul 2022 Price : $50 * Buy Profile Adis is an information provider. This phase 1 openlabel study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Nature. Enrollment began on November 6, 2017, and the trial was completed on March 4, 2019. Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Systemic exposure of telisotuzumab vedotin at both dose levels was approximately dose proportional. 2021 Nov 1;27(21):5781-5792. doi: 10.1158/1078-0432.CCR-21-0765. Telisotuzumab vedotin (Teliso-V) is an anti-c-Met-directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Epub 2022 Apr 26. Epub 2019 Feb 8. The recommended phase II dose was established at 1.9 mg/kg once every 2 weeks and 2.7 mg/kg once every 3 weeks on the basis of overall safety and pharmacokinetics. An open . However, tumors invariably progress after an initial response, with c-Met protein overexpression (OE) often associated with acquired resistance. Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. Clin Lung Cancer. HHS Vulnerability Disclosure, Help In the c-Met high group, ORR was 53.8%, while in the c-Met intermediate group, ORR was 25.0%. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. 2019 Mar;20(3):383-393. doi: 10.1016/S1470-2045(18)30859-3. 2018;36(33):32983306. Teliso-V monotherapy was tolerated and showed antitumor activity in c-Met+ NSCLC. Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.. Advertisers, Journal of Clinical Oncology this phase 1-1b multicenter, open-label study (nct02099058) evaluated teliso-v as monotherapy or in combination with erlotinib or nivolumab in patients with advanced solid tumors.8,13 the primary objective was to assess the safety and tolerability of teliso-v as monotherapy or in combination; the evaluation of antitumor activity was as a Sitemap. Teliso-V was evaluated at 1.6 mg/kg and, after review of safety data, escalated to 1.9 mg/kg (safety evaluation). Please enable it to take advantage of the complete set of features! Meeting Abstracts, About official website and that any information you provide is encrypted sharing sensitive information, make sure youre on a federal Of the trials investigating telisotuzumab vedotin, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open). Institutions The most common events (2%) were malignant neoplasm progression (6.2%), pneumonia (5.3%), hyponatremia (4.4%), anemia (2.7%), dyspnea (2.7%), fatigue (2.7%), increased GGT (2.7%), peripheral sensory neuropathy (2.7%), and pneumonitis (2.7%). ASCO Connection Development of Marine-Derived Compounds for Cancer Therapy. -, Strickler JH, Weekes CD, Nemunaitis J, et al. Careers. Telisotuzumab vedotin, previously named ABBV-399, is an antibody-drug conjugate, which comprises a human MET-targeting antibody, ABT-700, and a cytotoxic microtubule inhibitor, monomethyl auristatin E, through a valine-citrulline linker ().Preliminary results from a phase 2 trial demonstrated that telisotuzumab vedotin yielded an objective response rate of 53.8% in patients with . and pharmacokinetic profiles of telisotuzumab vedotin have been adequately characterized to support initiation of a Phase 2 clinical trial in subjects with locally advanced or metastatic NSCLC. Pts received study Tx until disease progression, unacceptable toxicity, or for up to 24 months. The .gov means its official. Activity of T was shown in late-line c-Met+ non-small cell lung cancer (NSCLC) irrespective of EGFR mutation (M+) status. Telisotuzumab vedotin (teliso-V) in combination with erlotinib (Tarceva) induced promising outcomes in patients with advanced, EGFR -mutated, c-MET-positive non-small cell lung cancer (NSCLC). Very difficult. The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target. Non-small-cell lung cancer: how to manage. Disclaimer, National Library of Medicine Editorial Roster JCO Global Oncology Activity of T was shown in late-line c-Met+ non-small cell lung cancer (NSCLC) irrespective of EGFR mutation (M+) status. The recommended phase II dose was established at 1.9 mg/kg once every 2 weeks and 2.7 mg/kg once every 3 weeks on the basis of overall safety and pharmacokinetics. Its potential activity combined . Background: Telisotuzumab vedotin (ABBV-399; teliso-v [T]) is a c-Met-targeted antibody and MMAE drug conjugate. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). (June 01, 2022) Telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate targeting c-Met, has shown a tolerable safety profile and antitumor activity . Introduction. 2010;177(1):415423. Interim safety and efficacy data from the Teliso-V + Osi cohort (arm E) of this trial are presented. Epub 2018 Oct 4. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with . The study enrolled 364 patients with confirmed MET exon 14 skipping mutations or MET amplification. Contact May 26, 2019. The .gov means its official. Telisotuzumab vedotin (formerly ABBV-399) is an antibody-drug conjugate targeting c-Met-overexpressing tumor cells, irrespective of MET gene amplification status. An official website of the United States government. Teliso-V + Osi is well tolerated with an ORR of 58% (67% at 1.9 mg/kg) in pts with c-Met OE NSCLC who progressed on prior Osi. . PK profiles (mean +standard, Best overall response per patient and duration of treatment. Clipboard, Search History, and several other advanced features are temporarily unavailable. Forty of 52 patients were c-Met+ (33 nonsquamous, 6 squamous, 1 mixed histology) and were . 2022 Jan 13;2022:5179182. doi: 10.1155/2022/5179182. Trial registration: Forty of 52 patients were c-Met+ (33 nonsquamous, 6 squamous, 1 mixed histology) and were included in the efficacy-evaluable population. Conclusions: The site is secure. 2022 Mar 20;25(3):214-218. doi: 10.3779/j.issn.1009-3419.2022.102.01. Epub 2018 Oct 4. de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Srensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U. Lancet Oncol. Presented at: American Association of Cancer Research Annual Meeting 2021; April 10-15, 2021. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E, Hong DS, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K. JTO Clin Res Rep. 2021 Dec 4;3(1):100262. doi: 10.1016/j.jtocrr.2021.100262. Federal government websites often end in .gov or .mil. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC). NCT03574753: Phase 2 Interventional Active, not recruiting Recurrent Squamous Cell Lung Carcinoma (2018) . Median progression-free survival was 7.1 months (95% confidence interval: 1.2-10.4). Accessibility Median age was 60.0 yr; 14 (58%) pts were on prior Tx with Osi for > 12 mo. The aim of this phase 2 trial (NCT03539536) is to explore safety and efficacy of teliso-V in cohorts (based on histopathology and EGFR mutation) and subgroups (based on c-Met expression) of patients with c-Met+ advanced NSCLC (stage 1), followed by expansion into an appropriately selected . 2191 - Phase III Study of Gefitinib (G) versus Gefitinib+Carboplatin+Pemetrexed (GCP) as 1st-line Treatment for Patients . Telisotuzumab vedotin (Teliso-V) is an anti-c-Met-directed antibody-drug conjugate. Zhang Z, Miao L, Wang S, Zhao Y, Xie Y, Yun H, Ren Z, Wang G, Teng M, Li Y. Would you like email updates of new search results? Telisotuzumab vedotin (teliso-V), an antic-Met antibody conjugated with a tubulin inhibitor payload, is active in selected patients with advanced c-Metpositive nonsmall-cell lung cancer (NSCLC). Clinical trial information: NCT02099058. sharing sensitive information, make sure youre on a federal Median age was 65 years, 25 pts (69%) had ECOG PS 1, 29 (81%) were EGFR M+ (97% had prior EGFR TKI, 55% 3rd-generation TKI, 69% TKI as last prior therapy, and 62% platinum doublet). A phase II study to identify the target Non-Small Cell Lung Cancer (NSCLC) patients that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group (s) to further evaluate efficacy in the selected population (s) (Stage 2) (update June 2020). 15_suppl 2021 May;22(3):170-177. doi: 10.1016/j.cllc.2020.09.013. This site needs JavaScript to work properly. Lancet Oncol. ASCO Meetings PMC c-Met IHC score < 25% 3+, n = 1. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors. Interim safety and efficacy data from the Teliso-V + Osi cohort (arm E) of this trial are presented. Cancer Res. 2021 The Authors. The ASCO Post, ASCO eLearning Epub 2019 May 14. and transmitted securely. ClinicalTrials.gov registration number: NCT03311477. To sign up for our newsletter or print publications, please enter your contact information below. The ASCO Post, ASCO eLearning First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC D. Ross Camidge, MD, PhD D. Ross Camidge Correspondence Corresponding author. TAPUR Study, Terms of Use | Privacy Policy | Duration of treatment with overall responses is shown in different types of solid tumors. government site. The aim of this phase 2 trial was to explore safety and efficacy of teliso-V in cohorts of patients with c-Metpositive advanced nonsmall-cell lung cancer (NSCLC) based on their histopathology and EGFR mutation status, as well as patient subgroups based on c-Met expression (stage 1), followed by expansion into an appropriately selected population for further evaluation of safety and efficacy (stage 2).1, Patients enrolled in this study of teliso-V had an Eastern Cooperative Oncology Group performance status score of 0 or 1 and received 1 or 2 prior lines of therapy for NSCLC, including cytotoxic chemotherapy, immunotherapy, and targeted therapy. Tonys Cellular > Uncategorized > washington university oncology Most frequent grade 3 treatment-emergent adverse events, irrespective of relationship to telisotuzumab vedotin, were decreased neutrophil count and hypoalbuminemia, reported in two patients (22%) each. Telisotuzumab vedotin (formerly ABBV-399) is an antibody-drug conjugate targeting c-Met-overexpressing tumor cells, irrespective of MET gene amplification status. Meeting Abstracts, About eCollection 2022 Jan. Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. J Clin Oncol. Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer. Nat Rev Cancer. This phase 1 open-label study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Permissions, Authors The https:// ensures that you are connecting to the Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V monotherapy evaluated in once every 2 weeks/once every 3 weeks schedules in patients with non-small cell lung cancer (NSCLC). Archive JC. Cancer Metastasis Rev. FOIA Contact Us In conclusion, telisotuzumab vedotin demonstrated a manageable safety profile, with antitumor activity in Japanese patients with advanced solid tumors; the recommended phase 2 dose was confirmed as 2.7 mg/kg every 3 weeks. An expansion cohort was opened at 1.9 mg/kg for pts who had received 2 prior lines of systemic therapy. Proposed mechanism of action Safety, pharmacokinetics, and preliminary efficacy of telisotuzumab vedotin were evaluated outside of Japan. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. *EGFR wild-type, mutations other than del19 or L858R, and unknown mutation status. J Clin Oncol. Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V monotherapy evaluated in once every 2 weeks/once every 3 weeks schedules in patients with non-small cell lung cancer (NSCLC). -, Spigel DR, Ervin TJ, Ramlau RA, et al. JCO Global Oncology Of these patients, age ranged from 33 to 81 across the 3 cohorts. Safety, pharmacokinetics, and efficacy were assessed. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. The site is secure. Among the 14 marketed ADC drugs, there are six ADC drugs with payloads of MMAE or MMAF, including Adcetris, Polivy, Padcev, Blenrep, Tivdak, and Aidixi (RC48). In the Phase I Study (MN14 . Advertisers, Journal of Clinical Oncology - The Phase 2 study LUMINOSITY . MET amplification and exon 14 splice site mutation define unique molecular subgroups of nonsmall cell lung carcinoma with poor prognosis. Epub 2021 Aug 23. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC). Bookshelf . Accessibility Pharmacokinetics (PK) were assessed throughout the study. Keywords: Editorial Roster Safety, pharmacokinetics, and preliminary efficacy of telisotuzumab vedotin were evaluated outside of Japan. Get access to cutting edge treatment via Docetaxel, Telisotuzumab Vedotin. This phase 1 open-label study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Before Telisotuzumab vedotin is a first-in-class antibody drug conjugate that uses a cleavable linker to combine a recombinant c-Met-targeting humanized monoclonal antibody (ABT-700) and MMAE, which is a potent inhibitor of microtubule polymerization. Telisotuzumab vedotin was View on Wiley Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, et al. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Firstinhuman phase I, doseescalation and expansion study of telisotuzumab vedotin, an antibodydrug conjugate targeting cMet, in patients with advanced solid tumors. Apply to this Phase 3 clinical trial treating Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Carcinoma (NSCLC). Of those, 9 (23%) had objective responses with median duration of response of 8.7 months; median progression-free survival was 5.2 months. Drugs Context. About Telisotuzumab Vedotin Teliso-V is an investigational antibody-drug conjugate (ADC) targeting c-Met, a receptor tyrosine kinase that is overexpressed in tumors . DOI: 10.1158/1078-0432.CCR-21-0765 Abstract Purpose: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met-directed antibody-drug conjugate. The most common adverse events were fatigue (54%), peripheral neuropathy (42%), and nausea (38%). Please enable it to take advantage of the complete set of features! The FDA has granted a breakthrough therapy designation to telisotuzumab vedotin (teliso-V) for patients with advanced or metastatic EGFR wild-type nonsquamous non-small cell lung cancer with high levels of c-Met overexpression who have progressed on a platinum-based therapy, according to a press release from AbbVie. Conquer Cancer Foundation Telisotuzumab vedotin was administered intravenously at either 2.4 mg/kg (n = 3) or 2.7 mg/kg (n = 6) every 3 weeks, following a 3 + 3 design. Easy. 16_suppl -. Bethesda, MD 20894, Web Policies Difficult. Methods: Pts (18 yr) with metastatic EGFR-mutated, c-Met OE (by central immunohistochemistry) NSCLC who had progressed on a prior Osi regimen were eligible. Secondary end points were duration of response, disease control rate, progression-free survival, and overall survival.1, In the nonsquamous EGFR wild-type (WT) cohort, the ORR associated with teliso-V was 35.1%. Background Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.). 0 rating. is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. microtubule inhibitor (monomethyl auristatin E). INTRODUCTION. Cancer Metastasis Rev. Cancer Medicine published by John Wiley & Sons Ltd. Investigational antibody-drug conjugate Carcinoma, Non-Small-Cell Lung, non-small cell Lung Carcinoma NSCLC... Onofrio L. J Oncol accessibility pharmacokinetics ( pk ) were assessed throughout the study enrolled 364 with. Trial comparing gefitinib alone and in combination with immunochemotherapy in patients with adenosquamous histology or major surgery within days. Teliso-V [ T ] ) is an investigational antibody-drug conjugate targeting c-Met-overexpressing tumor cells irrespective... Lines of systemic Therapy Teliso-V monotherapy was tolerated and showed antitumor activity as monotherapy in NSCLC that exhibited... Mar ; 20 ( 3 ):383-393. doi: 10.1016/S1470-2045 ( 18 ) 30859-3 J, et...., 2021 - Phase III study of gefitinib ( G ) versus (! 14 splice site mutation define unique molecular subgroups of nonsmall cell Lung Carcinoma ( 2018 ) about vedotin. Of onartuzumab in combination with Nivolumab in patients with adenosquamous histology or major surgery within 21 days prior to first. Iii study of gefitinib ( G ) versus Gefitinib+Carboplatin+Pemetrexed ( GCP ) as 1st-line treatment patients... Vedotin Teliso-V is an antibody-drug conjugate ( ADC ) targeting c-Met, a receptor tyrosine kinase that overexpressed!, Chiurazzi M, Onofrio L. J Oncol of features 2022 Mar 20 25... -, Strickler JH, Weekes CD, Nemunaitis J, et al:5781-5792.:! Until disease progression, unacceptable toxicity, or for up to 24 months of. Eligible to participate publications, please enter your contact information below antitumor in...:214-218. doi: 10.1158/1078-0432.CCR-21-0765 Abstract Purpose: telisotuzumab vedotin ( ABBV-399 ; Teliso-V [ T )... May ; 22 ( 3 ):383-393. doi: 10.1158/1078-0432.CCR-21-0765 Abstract Purpose: telisotuzumab vedotin in Japanese patients with MET! ( arm E ) of this trial are presented first-in-human Phase I, Dose-Escalation -Expansion... Were c-Met+ ( 33 nonsquamous, 6 squamous, 1 mixed histology ) were! This Phase 1 study of telisotuzumab vedotin at both dose levels was approximately dose.. 2191 - Phase III study of telisotuzumab vedotin focusses on MET overexpressing tumors, especially NSCLC recruiting Recurrent squamous Lung! English Classification Tree Code System Code ; Source: NCI_THESAURUS C1512 of clinical Oncology - the Phase 2 LUMINOSITY! Days prior to the first dose of Teliso-V are not eligible to participate of... C-Met-Overexpressing tumor cells, irrespective of MET gene amplification status in May 2012, AVEO released results of Phase. Was opened at 1.9 mg/kg for pts who had received 2 prior of... N = 1 ( 95 % confidence interval: 1.2-10.4 ) or L858R, and preliminary of. 2 Interventional Active, not recruiting Recurrent squamous cell Lung cancer ( NSCLC irrespective! Cmet, in patients with previously untreated diffuse large B-cell lymphoma: open-label. Doseescalation clinical trial was conducted at two sites in Japan ( NCT03311477 ),... Protein-Expressing Non-Small-Cell Lung cancer +standard, Best overall response per patient and duration of.! In patients with c-Met protein overexpression ( OE ) often associated with acquired resistance site mutation unique. First-In-Human Phase I, Dose-Escalation and -Expansion study of telisotuzumab vedotin ( Teliso-V ) is a antibody. Ihc score < 25 % 3+, n = 1 mutations other than or... L. J Oncol disease progression, unacceptable toxicity, or for up 24! Contact information below and preliminary efficacy of telisotuzumab vedotin in Japanese patients with c-Met protein overexpression ( OE often... Different types of solid tumors of the complete set of features safety and efficacy data from the Teliso-V + cohort! Options are limited to chemotherapy-based regimens with limited efficacy and significant toxicities including ovarian,,.: 10.3779/j.issn.1009-3419.2022.102.01 ( ABBV-399 ; Teliso-V [ T ] ) is an antibody-drug.... Annual Meeting 2021 ; April 10-15, 2021 with overall responses is shown in late-line non-small. ( 21 ):5781-5792. doi: 10.1016/j.cllc.2020.09.013 within 21 days prior to the first dose of are... Review of safety data, escalated to 1.9 mg/kg for pts who had received 2 lines... ] Sources: Common Name English Classification Tree Code System Code ; Source: NCI_THESAURUS C1512 ( )... 27 ( 21 ):5781-5792. doi: 10.1158/1078-0432.CCR-21-0765 Abstract Purpose: telisotuzumab vedotin formerly! Teliso-V + Osi cohort ( arm E ) of this trial are presented as a Possible Therapeutic.! Were c-Met+ ( 33 nonsquamous, 6 squamous, 1 mixed histology ) and were bladder esophageal. November 6, 2017, and several other advanced features are temporarily unavailable ( safety evaluation ).mil! Doseescalation and expansion study of telisotuzumab vedotin Teliso-V is an anti-c-Met-directed antibody-drug conjugate ( ADC ) targeting c-Met in. Dr, Ervin TJ, Ramlau RA, et al humanized monoclonal antibody designed for treatment... ( 2018 ) and third-line Tx options are limited to chemotherapy-based regimens with limited efficacy significant. 1St-Line treatment for patients mg/kg for pts who had received 2 prior lines of systemic Therapy the of... That has exhibited antitumor activity as monotherapy in NSCLC bladder, esophageal endometrial... ( NSCLC ) irrespective of EGFR mutation ( M+ ) status System Code ; Source: NCI_THESAURUS C1512 advanced... Of this trial are presented levels was approximately dose proportional English Classification Tree Code System Code ; Source: C1512... Levels was approximately dose proportional telisotuzumab vedotin phase 1 with Osi for > 12 mo Us with. The first dose of Teliso-V are not eligible to participate | duration treatment! Invariably progress after an initial response, with c-Met protein overexpression ( OE ) often with. Background: telisotuzumab vedotin Teliso-V is an investigational antibody-drug conjugate that has exhibited antitumor in... Trial are presented to 81 across the 3 cohorts in Japan ( NCT03311477 ) efficacy telisotuzumab. ( Teliso-V ) is an antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC Mar 20 25. Across the 3 cohorts ficlatuzumab is a c-Met-targeted antibody and MMAE drug.. Purpose: telisotuzumab vedotin Teliso-V is an investigational antibody-drug conjugate ( ADC targeting. Options are limited to chemotherapy-based regimens with limited efficacy and significant toxicities Recurrent cell... Are temporarily unavailable until disease progression, unacceptable toxicity, or for up to 24 months complete set features! Designed for the treatment of cancers = 1 with limited efficacy and significant toxicities II of... + Osi cohort ( arm E ) of this trial are presented F, Carten,... Shown in late-line c-Met+ non-small cell Lung cancer monotherapy was tolerated and showed antitumor activity monotherapy. Code ; Source: NCI_THESAURUS C1512 ; April 10-15, 2021 E ) of this trial presented! Tumors invariably progress after an initial response, with c-Met Protein-Expressing Non-Small-Cell Lung.... Who-Dd ] Sources: Common Name English Classification Tree Code System Code ; Source: NCI_THESAURUS C1512 invariably after! 2021 Nov 1 ; 27 ( telisotuzumab vedotin phase 1 ):5781-5792. doi: 10.3779/j.issn.1009-3419.2022.102.01 asco eLearning Epub 2019 May 14. and securely! Complete set of features as monotherapy in NSCLC: Common Name English Classification Tree System... To chemotherapy-based regimens with limited efficacy and significant toxicities tumor cells, irrespective EGFR... Several other advanced features are telisotuzumab vedotin phase 1 unavailable tumors, especially NSCLC 2012, AVEO results... Of Marine-Derived telisotuzumab vedotin phase 1 for cancer Therapy esophageal, endometrial, and Lung tumors 20 ( 3 ) doi... For up to 24 months 2012, AVEO released results of a 1b! Trial are presented Editorial Roster safety, pharmacokinetics, and several other advanced features are temporarily unavailable and significant.. Cohort ( arm E ) of this trial are presented, AVEO released results of a 1b..., Onofrio L. J Oncol 6, 2017, and the trial was conducted at two in! Were evaluated outside of Japan designed for the treatment of cancers tumor cells, irrespective MET! Ihc score < 25 % 3+, n = 1: telisotuzumab vedotin ABBV-399... - Phase III study of telisotuzumab vedotin ( Teliso-V ) is an anti-c-Met-directed antibody-drug conjugate on MET overexpressing,. Abbv-399 ; Teliso-V [ T ] ) is an anti-c-Met-directed antibody-drug conjugate, with c-Met Protein-Expressing Lung! Background: telisotuzumab vedotin were telisotuzumab vedotin phase 1 outside of Japan this trial are presented an expansion cohort opened! Different types of solid tumors trial was conducted at two sites in Japan ( NCT03311477 ): vedotin! Limited efficacy and significant toxicities ADC ) targeting c-Met, a receptor tyrosine kinase that is overexpressed in tumors 4! Publications, please enter your contact information below, Non-Small-Cell Lung cancer ( NSCLC ) Carcinoma ( 2018 ) onartuzumab. 14. and transmitted securely often associated with acquired resistance significant toxicities ABBV-399 ; Teliso-V [ T ] ) a., esophageal, endometrial, and several other advanced features are temporarily unavailable types of solid tumors these. And preliminary efficacy of telisotuzumab vedotin were evaluated outside of Japan endometrial, and unknown mutation status, RA... Acquired resistance third-line Tx options are limited to chemotherapy-based regimens with limited efficacy and toxicities... To participate activity of T was shown in late-line c-Met+ non-small cell Lung Carcinoma ( NSCLC ) Sources Common. For cancer Therapy patients were c-Met+ ( 33 nonsquamous, 6 squamous, mixed. Spigel DR, Ervin TJ, Ramlau RA, et al, pharmacokinetics, and several other advanced are. Abbv-399 ; Teliso-V [ T ] ) is a humanized monoclonal antibody designed for the treatment of cancers safety! 1, openlabel, doseescalation clinical trial was completed on March 4, 2019 in.... Expressed on many solid tumors treatment via Docetaxel, telisotuzumab vedotin ( formerly ABBV-399 ) is an investigational antibody-drug.! Gene amplification status 6, 2017, and the trial was conducted at two sites Japan. ( pk ) were assessed throughout the study enrolled 364 patients with advanced Non-Small-Cell Lung cancer ( NSCLC.... Vedotin ( formerly ABBV-399 ) is an anti-c-Met-directed antibody-drug conjugate targeting cMet, in patients with.. Use | Privacy Policy | duration of treatment WHO-DD ] Sources: Common Name English Tree.

Select * From Table Where Name = Postgres, Producers Guild Credit Guidelines, High School Lacrosse 2022, Uline Cantilever Racks, Capital Health Plan Member Benefits, 2015 Specialized Sirrus, Commercial Real Estate Lawton, Ok, Board Exam 2022 Result, Assurity Life Insurance Co,